Relationships between relapse-associated SNPs and pharmacokinetics and pharmacodynamics of antileukemic drugs
SNP information . | Association with ALL relapse . | Association with asparaginase antibody . | ||||||
---|---|---|---|---|---|---|---|---|
SNP ID . | Chr . | Position . | Gene . | MAF . | P . | Risk allele . | P . | The allele with higher antibody . |
rs251177 | 5 | 141007068 | FCHSD1 | 0.22 | 6.53 × 10−5 | C | .0053 | C |
rs6773449 | 3 | 26322367 | 0.03 | 2.15 × 10−4 | C | .043 | C |
SNP information . | Association with ALL relapse . | Association with asparaginase antibody . | ||||||
---|---|---|---|---|---|---|---|---|
SNP ID . | Chr . | Position . | Gene . | MAF . | P . | Risk allele . | P . | The allele with higher antibody . |
rs251177 | 5 | 141007068 | FCHSD1 | 0.22 | 6.53 × 10−5 | C | .0053 | C |
rs6773449 | 3 | 26322367 | 0.03 | 2.15 × 10−4 | C | .043 | C |
. | Association with dexamethasone clearance . | |||||||
---|---|---|---|---|---|---|---|---|
P . | The allele with higher clearance . | |||||||
rs6007758 | 22 | 46668860 | 0.01 | 3.74 × 10−5 | A | .038 | A | |
rs41488548 | 11 | 32432060 | 0.07 | 6.03 × 10−5 | A | .0052 | A | |
rs10264856 | 7 | 87100517 | ABCB1; RUNDC3B | 0.11 | 1.84 × 10−4 | T | .029 | T |
rs4728709 | 7 | 87071538 | ABCB1 | 0.11 | 3.06 × 10−4 | A | .0083 | A |
. | Association with dexamethasone clearance . | |||||||
---|---|---|---|---|---|---|---|---|
P . | The allele with higher clearance . | |||||||
rs6007758 | 22 | 46668860 | 0.01 | 3.74 × 10−5 | A | .038 | A | |
rs41488548 | 11 | 32432060 | 0.07 | 6.03 × 10−5 | A | .0052 | A | |
rs10264856 | 7 | 87100517 | ABCB1; RUNDC3B | 0.11 | 1.84 × 10−4 | T | .029 | T |
rs4728709 | 7 | 87071538 | ABCB1 | 0.11 | 3.06 × 10−4 | A | .0083 | A |
. | Association with MTXPG accumulation . | |||||||
---|---|---|---|---|---|---|---|---|
P . | The allele with lower MTXPG . | |||||||
rs6683977 | 1 | 66541688 | PDE4B | 0.45 | 5.13 × 10−6 | C | .042 | C |
rs524770 | 1 | 66538810 | PDE4B | 0.42 | 9.12 × 10−5 | A | .0042 | A |
rs641262 | 1 | 66545937 | PDE4B | 0.45 | 9.47 × 10−5 | A | .017 | A |
rs4265132 | 7 | 118907598 | 0.04 | 2.01 × 10−4 | T | .047 | T | |
rs16965335 | 15 | 51023401 | 0.03 | 2.31 × 10−4 | T | .013 | T |
. | Association with MTXPG accumulation . | |||||||
---|---|---|---|---|---|---|---|---|
P . | The allele with lower MTXPG . | |||||||
rs6683977 | 1 | 66541688 | PDE4B | 0.45 | 5.13 × 10−6 | C | .042 | C |
rs524770 | 1 | 66538810 | PDE4B | 0.42 | 9.12 × 10−5 | A | .0042 | A |
rs641262 | 1 | 66545937 | PDE4B | 0.45 | 9.47 × 10−5 | A | .017 | A |
rs4265132 | 7 | 118907598 | 0.04 | 2.01 × 10−4 | T | .047 | T | |
rs16965335 | 15 | 51023401 | 0.03 | 2.31 × 10−4 | T | .013 | T |
. | Association with MTX clearance . | |||||||
---|---|---|---|---|---|---|---|---|
P . | The allele with higher clearance . | |||||||
rs7141601 | 14 | 83865815 | 0.13 | 1.44 × 10−4 | A | .017 | A | |
rs2613079 | 4 | 181846695 | 0.01 | 2.02 × 10−4 | A | .023 | A | |
rs12751530 | 1 | 41129367 | 0.17 | 2.45 × 10−4 | G | .034 | G |
. | Association with MTX clearance . | |||||||
---|---|---|---|---|---|---|---|---|
P . | The allele with higher clearance . | |||||||
rs7141601 | 14 | 83865815 | 0.13 | 1.44 × 10−4 | A | .017 | A | |
rs2613079 | 4 | 181846695 | 0.01 | 2.02 × 10−4 | A | .023 | A | |
rs12751530 | 1 | 41129367 | 0.17 | 2.45 × 10−4 | G | .034 | G |
Chromosomal position is based on hg19. P values indicate the statistical significance of the associations of SNP genotypes with ALL relapse (determined by Fine and Gray hazard regression model) and with pharmacokinetic and pharmacodynamic phenotypes (determined by linear regression).
chr indicates chromosome; MAF, minor allele frequency; MTX, methotrexate; and MTXPG, methotrexate polyglutamate.